INTRODUCTION: Inositol and its derivatives comprise a huge field of biology. Myo-inositol is not only a prominent component of membrane-incorporated phosphatidylinositol, but participates in its free form, with its isomers or its phosphate derivatives, to a multitude of cellular processes, including ion channel permeability, metabolic homeostasis, mRNA export and translation, cytoskeleton remodeling, stress response. AREAS COVERED: Bioavailability, safety, uptake and metabolism of inositol is discussed emphasizing the complexity of interconnected pathways leading to phosphoinositides, inositol phosphates and more complex molecules, like glycosyl-phosphatidylinositols. EXPERT OPINION: Besides being a structural element, myo-inositol exerts unexpected functions, mostly unknown. However, several reports indicate that inositol plays a key role during phenotypic transitions and developmental phases. Furthermore, dysfunctions in the regulation of inositol metabolism have been implicated in several chronic diseases. Clinical trials using inositol in pharmacological doses provide amazing results in the management of gynecological diseases, respiratory stress syndrome, Alzheimer's disease, metabolic syndrome, and cancer, for which conventional treatments are disappointing. However, despite the widespread studies carried out to identify inositol-based effects, no comprehensive understanding of inositol-based mechanisms has been achieved. An integrated metabolomics-genomic study to identify the cellular fate of therapeutically administered myo-inositol and its genomic/enzymatic targets is urgently warranted.

Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease / Bizzarri, Mariano; Fuso, Andrea; Dinicola, Simona; Cucina, Alessandra; Bevilacqua, Arturo. - In: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. - ISSN 1742-5255. - ELETTRONICO. - 12:10(2016), pp. 1181-1196. [10.1080/17425255.2016.1206887]

Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease

BIZZARRI, Mariano;FUSO, ANDREA;DINICOLA, SIMONA;CUCINA, Alessandra;BEVILACQUA, Arturo
2016

Abstract

INTRODUCTION: Inositol and its derivatives comprise a huge field of biology. Myo-inositol is not only a prominent component of membrane-incorporated phosphatidylinositol, but participates in its free form, with its isomers or its phosphate derivatives, to a multitude of cellular processes, including ion channel permeability, metabolic homeostasis, mRNA export and translation, cytoskeleton remodeling, stress response. AREAS COVERED: Bioavailability, safety, uptake and metabolism of inositol is discussed emphasizing the complexity of interconnected pathways leading to phosphoinositides, inositol phosphates and more complex molecules, like glycosyl-phosphatidylinositols. EXPERT OPINION: Besides being a structural element, myo-inositol exerts unexpected functions, mostly unknown. However, several reports indicate that inositol plays a key role during phenotypic transitions and developmental phases. Furthermore, dysfunctions in the regulation of inositol metabolism have been implicated in several chronic diseases. Clinical trials using inositol in pharmacological doses provide amazing results in the management of gynecological diseases, respiratory stress syndrome, Alzheimer's disease, metabolic syndrome, and cancer, for which conventional treatments are disappointing. However, despite the widespread studies carried out to identify inositol-based effects, no comprehensive understanding of inositol-based mechanisms has been achieved. An integrated metabolomics-genomic study to identify the cellular fate of therapeutically administered myo-inositol and its genomic/enzymatic targets is urgently warranted.
2016
cell signalling; inositol phosphates; inositolphosphoglycans; Myo-inositol; phosphoinositides; Toxicology; Pharmacology
01 Pubblicazione su rivista::01a Articolo in rivista
Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease / Bizzarri, Mariano; Fuso, Andrea; Dinicola, Simona; Cucina, Alessandra; Bevilacqua, Arturo. - In: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. - ISSN 1742-5255. - ELETTRONICO. - 12:10(2016), pp. 1181-1196. [10.1080/17425255.2016.1206887]
File allegati a questo prodotto
File Dimensione Formato  
Bizzarri_Inositol_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.2 MB
Formato Adobe PDF
2.2 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/957333
Citazioni
  • ???jsp.display-item.citation.pmc??? 67
  • Scopus 139
  • ???jsp.display-item.citation.isi??? 113
social impact